Pfizer will allow its COVID-19 pill to be made and sold cheaply in 95 low-income countries, the company announced Tuesday. “The fact that we now have two manufacturer-anywhere licenses for these two drugs is a big change, and it draws a big contrast with the restrictive licensing so far for vaccines,” said James Love of Knowledge Ecology International. (The New York Times)

U.S. COVID-19 cases will need to drop below 10,000 per day in order for the country to get back to “normality,” Dr. Anthony Fauci said. This week, the U.S. has reported an average of about 83,500 new COVID-19 cases per day. (CNBC Weekly)

ViaCyte and CRISPR have developed a new cell therapy for type 1 diabetes from gene-edited, immune-evasive stem cells and will be testing it in a new clinical trial. The companies expect to begin patient enrollment by the end of the year. (Endpoints News)

Moderna is in the process of agreeing to donate millions more COVID-19 vaccine doses to low- and middle-income countries in 2022. Under the preliminary agreement, which is not yet finalized, Moderna would sell its vaccine to COVAX at the lower price of $7 per dose. (POLITICO)

General Electric is spinning off its healthcare business, GE Healthcare, in 2023. The company, which develops MRI and ultrasound equipment, will face growing competition from startups in the diagnostic-imaging-equipment market. (The Wall Street Journal)